Global Partners L.P. (GLP)
NYSE NYSE Primary 
One in Every Five U.S. Homes Using GLP-1s: What it Means for Consumer Trends
MichaelAaron Flicker examines the growing impact of GLP-1 medications on consumer behavior, noting that roughly one in five American households has someone using a GLP-1 drug. He explains how that trend is reshaping spending habits and discusses the implications for restaurants as well as food and beverage stocks.
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1
Viking Therapeutics just launched its next-gen weight loss program. Novo Nordisk and Eli Lilly are already deep into the development process with comparable programs.
3 Refining & Marketing MLPs With Strong Industry Tailwinds
Following a careful analysis of the Zacks Oil and Gas - Refining & Marketing MLP industry, we advise keeping an eye on three stocks: SPH, NGL and GLP.
Fractyl Health Says Revita Helped Patients Keep Weight Off After Stopping GLP-1s
Fractyl Health NASDAQ: GUTS reported one-year data from the randomized midpoint cohort of its REMAIN-1 study, saying its Revita procedure helped patients maintain a larger share of GLP-1-induced weight loss after discontinuing GLP-1 therapy compared with a sham procedure.
Poolbeg Pharma raises £3.5m to support key trial and GLP-1 progress
Poolbeg Pharma PLC (AIM:POLB), the clinical-stage biopharmaceutical, has raised £3.5 million before expenses through a share placing. Cathal Friel, executive chair, subscribed for £250,000 of the placing.
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Vivani Medical believes a tiny implant placed under the skin could help address the biggest issue with blockbuster GLP-1s: keeping patients on treatment to maintain their weight loss. The biotech company is in the early stages of developing an experimental implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic.
GLP-1s changed one woman's battle with bulimia, we put fitness trackers to the test, and panic pouches are on the rise. Read more in this week's Health newsletter:
Plus, how fitness trackers stack up against each other and the popularity of panic pouches.
3 High Growth GLP-1 Biotech Winners to Buy in July
The GLP-1 trade has matured from a single-stock story into a tiered opportunity set.
Wall Street Is Betting on Eli Lilly's GLP-1 Portfolio — It's Missing the $1 Trillion Opportunity
The pharmaceutical industry is entering a new era where biology and artificial intelligence are converging.
Novo Nordisk shares dip as latest prescription data points to GLP-1 pill slowdown
Shares in Novo Nordisk (NYSE:NVO) fell 2.5% to DKK319.20 after Deutsche Bank pointed to a continued slowdown in the oral version of the company's Wegovy weight-loss drug in the US. The bank published its weekly tracker of prescription data for Novo's GLP-1 franchise, the class of appetite-suppressing treatments that has driven the company's growth.
Kailera's GLP-1 drug meets main goal of late-stage trials
Kailera Therapeutics said on Tuesday its GLP-1 drug for patients with diabetes and obesity met the main goal of two-late stage trials.
Nestle to Tweak Some Food Recipes to Appeal to Duller GLP-1 Palates
Nestle is looking to spice up some of its products to counter duller taste buds that can accompany GLP-1 weight-loss drugs.
